logo.png
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024
24 oct. 2024 12h08 HE | Oryzon Genomics, S.A.
Final data from PORTICO, global Phase IIb vafidemstat trial in BPD, presented at the 37th ECNP annual conference in SeptemberCompany moving forward with PORTICO-2 Phase III trial preparations...
logo.png
ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder
01 oct. 2024 07h00 HE | Oryzon Genomics, S.A.
FDA’s feedback supports the initiation of the Phase III trialAgitation-Aggression in Borderline Personality Disorder (BPD) acknowledged as a possible therapeutic indicationOryzon may use STAXI-2 Trait...
logo.png
ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress
23 sept. 2024 08h00 HE | Oryzon Genomics, S.A.
Strong improvement in State-Trait Anger Expression Inventory 2 (STAXI-2) Trait Anger, a measure of agitation and aggression, at Weeks 8–12 compared to previous top line data; nominal statistical...
logo.png
ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder
11 sept. 2024 12h07 HE | Oryzon Genomics, S.A.
MADRID and CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
logo.png
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia
09 sept. 2024 08h00 HE | Oryzon Genomics, S.A.
Exploring the triple combination with venetoclax and azacitidineStudy sponsored by Oregon Health & Science University (OHSU) MADRID and CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) --...
logo.png
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat with Additional “Decision to Grant” Communications
03 sept. 2024 08h00 HE | Oryzon Genomics, S.A.
In Australia, Malaysia and Mexico MADRID and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company...
logo.png
ORYZON to Provide Corporate Progress Updates at Several Events in September
29 août 2024 08h14 HE | Oryzon Genomics, S.A.
German Fall Conference 2024European College of Neuropsychopharmacology (ECNP) congress 2024Sachs Annual Biotech in Europe Forum 2024 MADRID, Spain and CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE...
logo.png
ORYZON reports financial results and corporate update for half-year ending June 30, 2024
31 juil. 2024 08h32 HE | Oryzon Genomics, S.A.
Company granted an End-of-Phase II meeting with the FDA to discuss plans for a registrational Phase III trial with vafidemstat in Borderline Personality Disorder (BPD)Final data from PORTICO, global...
logo.png
ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan
08 juil. 2024 08h00 HE | Oryzon Genomics, S.A.
MADRID and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
logo.png
ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders
28 juin 2024 09h28 HE | Oryzon Genomics, S.A.
All resolutions were approvedAdditional resolution to increase capital for up to 100 million euros approved42.6867% of the issued shares represented MADRID and CAMBRIDGE, Mass., June 28, 2024 ...